Pegfilgrastim

Pegfilgrastim
Clinical data
Trade names	Neulasta
Biosimilars	pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, pegfilgrastim-fpgk, pegfilgrastim-jmdb, pegfilgrastim-pbbk, Cegfila, Filpegla, Fulphila, Fylnetra, Grasustek, Lapelga, Neutropeg, Nyvepria, Pelgraz, Pelmeg, Ristempa, Stimufend, Tezmota, Udenyca, Ziextenzo
AHFS/Drugs.com	Monograph
MedlinePlus	a607058
License data	EU EMA: by INN; US DailyMed: Pegfilgrastim;
Pregnancy; category	AU: B3;
Routes of; administration	Subcutaneous
Drug class	Hematopoietic agents, colony-stimulating factors, immunostimulants
ATC code	L03AA13 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	15–80 hrs
Identifiers
	IUPAC name N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene);
CAS Number	208265-92-3 ;
IUPHAR/BPS	6969;
DrugBank	DB00019 ;
ChemSpider	none;
UNII	3A58010674;
KEGG	D06889 ;
ChEMBL	ChEMBL1201568 ;
ECHA InfoCard	100.169.155
Chemical and physical data
Formula	C845H1343N223O243S9
Molar mass	18802.90 g·mol−1
	(what is this?) (verify)

Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).

Pegfilgrastim was approved for medical use in the United States in January 2002, in the European Union in August 2002, and in Australia in September 2002. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.